Objective: To study the clinical efficacy of Zisui Shengxue capsule in the treatment of chronic aplastic anemia. Method: Totally 64 patients with chronic aplastic anemia were randomized into the control group (treated with cyclosporin A and andriol) and the observation group (given Zisui Shengxue capsule beside the therapy for the control group) according to the random number method

with 32 cases in each group. The clinical efficacy

hemoglobin (Hb)

white blood cell (WBC)

platelet (PLT) before and after the treatment

and the adverse reactions during the treatment in the two groups were observed and compared. Result: Compared with the control group

the total effective rate significantly increased in the observation group (81.25% VS 56.25%

P <0.05).Compared with the control group

the total effective rate for TCM syndromes significantly increased in the observation group (96.875% VS 78.125%

P <0.05).Compared with the control group

the levels of Hb (80.32±21.27 VS 69.78±20.13) g · L-1

WBC (3.92±1.11 VS 3.14±1.08)×109/L and PLT (46.37±14.32 VS 31.08±13.82)×109/L significantly increased in the observation group after the treatment (P <0.05).Compared with the control group

adverse reactions

such as hirsutism (6.25% VS 28.125%)

hands shaking (12.50% VS 37.50%) and gingival hyperplasia (6.25% VS 25.00%) significantly reduced in the observation group (P <0.05). Conclusion: Zisui Shengxue capsule shows significant efficacy and less adverse reactions in treating chronic aplastic anemia

and can obviously improve the patients' hemogram indexes. It is worthy of clinical promotion.